Kevin Li

Kevin Li, M.D., is a Principal at Frazier Life Sciences, where he focuses on investment opportunities in the biopharmaceutical sector. He joined Frazier Life Sciences in 2021 and is based in Palo Alto, CA, contributing to the firm’s strategy of investing in innovative therapeutics across both private and public markets. His responsibilities include sourcing and evaluating biotechnology companies and supporting portfolio management in the development and commercialization of novel drug candidates.

Before joining Frazier, Dr. Li served as a Resident Physician in Internal Medicine at Stanford Health Care, where he honed his medical and clinical expertise. He also gained venture capital experience as a Summer Associate at Frazier Healthcare Partners, providing a strong foundation for his current role in life sciences investing.

Dr. Li holds a medical degree from Stanford University School of Medicine and a degree from Yale University, equipping him with deep clinical and scientific insight. He is recognized for his work in healthcare venture capital, particularly in supporting early-stage and growth-stage biopharmaceutical companies targeting unmet medical needs in therapeutics.